Last reviewed · How we verify
MM120
At a glance
| Generic name | MM120 |
|---|---|
| Also known as | MM-120, DT120, lysergide tartrate |
| Sponsor | Definium Therapeutics US, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge) (PHASE3)
- A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) (PHASE3)
- A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) (PHASE3)
- A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms (PHASE2)
- Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MM120 CI brief — competitive landscape report
- MM120 updates RSS · CI watch RSS
- Definium Therapeutics US, Inc. portfolio CI